These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 7036923)

  • 1. Aminoglycoside dosing in renal transplant patients. Comparison of nomogram and individualized pharmacokinetic methods in patients with shifting renal function.
    Tofte RW; Canafax DM; Simmons RL; Peterson PK
    Ann Surg; 1982 Mar; 195(3):287-93. PubMed ID: 7036923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative study of ototoxicity and nephrotoxicity in patients randomly assigned to treatment with amikacin or gentamicin.
    Lerner SA; Schmitt BA; Seligsohn R; Matz GJ
    Am J Med; 1986 Jun; 80(6B):98-104. PubMed ID: 3524221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum concentrations and inhibitory ratios during amikacin therapy of gram-negative infections.
    Farchione LA; Chudzik GM
    J Clin Pharmacol; 1978; 18(8-9):432-8. PubMed ID: 690253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amikacin serum concentrations: prediction of levels and dosage guidelines.
    Sarubbi FA; Hull JH
    Ann Intern Med; 1978 Nov; 89(5 Pt 1):612-8. PubMed ID: 717929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic and clinical studies with amikacin, a new aminoglycoside antibiotic.
    Lode H; Grunert K; Koeppe P; Langmaack H
    J Infect Dis; 1976 Nov; 134 SUPPL():S316-22. PubMed ID: 825589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal and Auditory toxic effects of amikacin in children with cancer.
    Faden H; Deshpande G; Grossi M
    Am J Dis Child; 1982 Mar; 136(3):223-5. PubMed ID: 7064947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amikacin for treatment of infections in patients with malignant diseases.
    Bodey GP; Rodriguez V; Valdivieso M; Feld R
    J Infect Dis; 1976 Nov; 134 SUPPL():S421-7. PubMed ID: 993633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of standard versus pharmacokinetically adjusted amikacin dosing in granulocytopenic cancer patients.
    Finley RS; Fortner CL; deJongh CA; Wade JC; Newman KA; Caplan E; Britten J; Wiernik PH; Schimpff SC
    Antimicrob Agents Chemother; 1982 Aug; 22(2):193-7. PubMed ID: 6765414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amikacin therapy of infections in neutropenic patients.
    Valdivieso M; Feld R; Rodriguez V; Bodey GP
    Am J Med Sci; 1975; 270(3):453-63. PubMed ID: 1108649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adaptation in neonatology of the once-daily concept of aminoglycoside administration: evaluation of a dosing chart for amikacin in an intensive care unit.
    Langhendries JP; Battisti O; Bertrand JM; François A; Kalenga M; Darimont J; Scalais E; Wallemacq P
    Biol Neonate; 1998 Nov; 74(5):351-62. PubMed ID: 9742264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ototoxicity of amikacin.
    Black RE; Lau WK; Weinstein RJ; Young LS; Hewitt WL
    Antimicrob Agents Chemother; 1976 Jun; 9(6):956-61. PubMed ID: 938024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amikacin therapy for serious gram-negative infection.
    Pollock AA; Berger SA; Richmond AS; Simberkoff MS; Rahal JJ
    JAMA; 1977 Feb; 237(6):562-4. PubMed ID: 576282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ototoxicity and pharmacokinetically determined dosages of amikacin in granulocytopenic cancer patients.
    Danhauer FJ; Fortner CL; Schimpff SC; deJongh CA; Wesley MN; Wiernik PH
    Clin Pharm; 1982; 1(6):539-43. PubMed ID: 7185540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy and toxicity of two dosing-regimens of amikacin in neonates with sepsis.
    Abdel-Hady E; El Hamamsy M; Hedaya M; Awad H
    J Clin Pharm Ther; 2011 Feb; 36(1):45-52. PubMed ID: 21198719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The necessity of increased doses of amikacin in burn patients.
    Zaske DE; Sawchuk RJ; Strate RG
    Surgery; 1978 Nov; 84(5):603-8. PubMed ID: 715674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical evaluation of amikacin in treatment of infections due to gram-negative aerobic bacilli.
    Mathias RG; Ronald AR; Gurwith MJ; McCullough DW; Stiver HG; Berger J; Cates CY; Fox LM; Lank BA
    J Infect Dis; 1976 Nov; 134 SUPPL():S394-401. PubMed ID: 825590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amikacin therapy of serious gram-negative bacillary infections in chronic hemodialysis patients.
    Meyer RD; Lewis RP; Finegold SM
    Chemotherapy; 1978; 24(3):172-8. PubMed ID: 657877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical experience with amikacin, a new aminoglycoside antibiotic.
    Theron FP; De Kock MA
    S Afr Med J; 1977 May; 51(21):746-8. PubMed ID: 327583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amikacin in treatment of infections caused by gram-negative bacteria resistant to gentamicin and other aminoglycosides: clinical and bacteriologic results.
    Daikos GK; Kosmidis JC; Hamilton-Miller JM; Brumfitt W
    J Infect Dis; 1976 Nov; 134 SUPPL():S286-90. PubMed ID: 993623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the nephrotoxicity and auditory toxicity of tobramycin and amikacin.
    Gatell JM; San Miguel JG; Zamora L; Araujo V; Bonet M; Bohé M; Jimenez de Anta MT; Farré M; Elena M; Ballesta A; Marin JL
    Antimicrob Agents Chemother; 1983 Jun; 23(6):897-901. PubMed ID: 6614894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.